KR20220143164A - 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 - Google Patents

치환된 리버스 피리미딘 ｂｍｉ-1 저해제 Download PDF

Info

Publication number
KR20220143164A
KR20220143164A KR1020227035587A KR20227035587A KR20220143164A KR 20220143164 A KR20220143164 A KR 20220143164A KR 1020227035587 A KR1020227035587 A KR 1020227035587A KR 20227035587 A KR20227035587 A KR 20227035587A KR 20220143164 A KR20220143164 A KR 20220143164A
Authority
KR
South Korea
Prior art keywords
diamine
fluoro
pyrimidine
benzimidazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227035587A
Other languages
English (en)
Korean (ko)
Inventor
창선 이
라밀 바이아지토브
리앙시안 카오
토마스 더블유. 데이비스
우 두
롱강 리우
영춘 문
스티븐 디. 페이젯
홍유 렌
나디야 시도렌코
리처드 제랄드 와일드
Original Assignee
피티씨 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피티씨 테라퓨틱스, 인크. filed Critical 피티씨 테라퓨틱스, 인크.
Publication of KR20220143164A publication Critical patent/KR20220143164A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
KR1020227035587A 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제 Ceased KR20220143164A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors
KR1020227002513A KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002513A Division KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Publications (1)

Publication Number Publication Date
KR20220143164A true KR20220143164A (ko) 2022-10-24

Family

ID=50776672

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227035587A Ceased KR20220143164A (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020217020963A Active KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020157016184A Active KR102275676B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227002513A Active KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217020963A Active KR102356487B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020157016184A Active KR102275676B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
KR1020227002513A Active KR102455889B1 (ko) 2012-11-21 2013-11-21 치환된 리버스 피리미딘 ｂｍｉ-1 저해제

Country Status (32)

Country Link
US (3) US10428050B2 (enExample)
EP (1) EP2922828B1 (enExample)
JP (3) JP6412503B2 (enExample)
KR (4) KR20220143164A (enExample)
CN (2) CN104918919A (enExample)
AR (1) AR093579A1 (enExample)
AU (1) AU2013348009C1 (enExample)
BR (1) BR112015011760B1 (enExample)
CA (1) CA2892045C (enExample)
CL (1) CL2015001377A1 (enExample)
CR (1) CR20150294A (enExample)
CU (1) CU24387B1 (enExample)
DK (1) DK2922828T3 (enExample)
EA (2) EA031405B1 (enExample)
EC (1) ECSP15019948A (enExample)
ES (1) ES2821529T3 (enExample)
HK (1) HK1215032A1 (enExample)
IL (2) IL238871B (enExample)
MA (1) MA38208B1 (enExample)
MX (2) MX385385B (enExample)
NI (1) NI201500072A (enExample)
NZ (2) NZ746607A (enExample)
PE (1) PE20151413A1 (enExample)
PH (1) PH12015501130B1 (enExample)
PL (1) PL2922828T3 (enExample)
PT (1) PT2922828T (enExample)
SA (1) SA517381847B1 (enExample)
SG (2) SG10201600149VA (enExample)
TW (1) TWI623531B (enExample)
UA (1) UA118094C2 (enExample)
WO (1) WO2014081906A2 (enExample)
ZA (1) ZA201503642B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6412503B2 (ja) 2012-11-21 2018-10-24 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014287121B2 (en) * 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
CA2922657C (en) 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
WO2017123826A1 (en) * 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
EP3580700A4 (en) 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
CN113784757A (zh) * 2019-01-15 2021-12-10 Ptc医疗公司 治疗急性髓性白血病的方法
US20220143016A1 (en) * 2019-02-28 2022-05-12 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
MX2021010906A (es) * 2019-03-11 2021-10-01 Ptc Therapeutics Inc Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas.
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
BR112021019170A2 (pt) * 2019-03-27 2022-03-03 Ptc Therapeutics Inc Combinações úteis em um método para tratar sarcoma
KR20210125558A (ko) * 2019-04-02 2021-10-18 하이노바 파마슈티컬스 인코포레이티드 방향족 아민계 화합물 및 이의 ar 및 brd4 이중 억제제 및 조절제의 제조에서의 용도
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
DE69530989T2 (de) 1994-08-13 2004-05-19 Yuhan Corp. Neue pyrimidinderivate und verfahren zu ihrer herstellung
IN188411B (enExample) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
DE60039059D1 (de) 1999-10-07 2008-07-10 Amgen Inc Triazin-kinase-hemmer
DE60024480T2 (de) 1999-10-27 2006-07-27 Novartis Ag Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
WO2001060816A1 (en) 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
AU2001242629B2 (en) 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
WO2002022604A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60136731D1 (de) 2000-09-20 2009-01-08 Ortho Mcneil Pharm Inc Pyrazine derivate als tyrosin kinase modulatoren
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
US7078410B2 (en) 2001-02-20 2006-07-18 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of GSK3-related disorders
WO2002070662A2 (en) 2001-03-02 2002-09-12 Gpc Biotech Ag Three hybrid assay system
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
JP4342937B2 (ja) 2001-07-03 2009-10-14 バーテックス ファーマシューティカルズ インコーポレイテッド ＳｒｃおよびＬｃｋタンパク質キナーゼの阻害剤としてのイソキサゾールピリミジン
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
CA2486187C (en) 2002-05-23 2013-02-19 Cytopia Pty Ltd. Kinase inhibitors
CA2490907C (en) 2002-06-28 2010-08-24 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
EP1713793A4 (en) 2004-02-04 2009-09-02 Smithkline Beecham Corp PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
TWI372624B (en) * 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
US20110098301A1 (en) 2005-03-10 2011-04-28 Bayer Healthcare Llc Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
JP2010505794A (ja) * 2006-10-03 2010-02-25 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用なインダゾリル誘導体
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
ZA200902384B (en) * 2006-10-19 2010-07-28 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
PE20081636A1 (es) 2007-01-26 2009-01-10 Smithkline Beecham Corp Inhibidores de antranilamida para aurora quinasa
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
CN101883764B (zh) 2007-12-07 2013-11-13 诺华股份有限公司 吡唑衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
EP2306836B1 (en) * 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
US8518952B2 (en) 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
JP2012501308A (ja) * 2008-09-02 2012-01-19 ノイロサーチ アクティーゼルスカブ ピラゾリルピリミジン誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
MX2011008444A (es) 2009-02-12 2011-09-06 Astellas Pharma Inc Derivado de heteroanillo.
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
ES2453097T3 (es) 2009-05-27 2014-04-04 Abbvie Inc. Inhibidores de pirimidina de actividad quinasa
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
SI3141252T1 (sl) * 2009-06-17 2018-12-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov influence
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
EP2454262B1 (en) 2009-07-15 2014-05-14 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
NZ601143A (en) 2010-01-12 2014-10-31 Ab Science Thiazole and oxazole kinase inhibitors
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
MX348419B (es) * 2010-08-19 2017-06-12 F Hoffmann-La Roche Ag * Conversion de celulas somaticas a celulas madre, neurales reprogramadas, inducidas (irnscs).
HRP20160094T1 (hr) 2010-09-13 2016-02-26 Novartis Ag Triazin-oksadiazoli
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
IN2013MN01519A (enExample) 2011-02-25 2015-06-12 Yuhan Corp
CA2840883C (en) * 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
JP6412503B2 (ja) * 2012-11-21 2018-10-24 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
MX2021010906A (es) * 2019-03-11 2021-10-01 Ptc Therapeutics Inc Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas.

Non-Patent Citations (72)

* Cited by examiner, † Cited by third party
Title
A. A. Alizadeh et al., Nature 403, 503 (2000).
A. Dutton et al., Blood 109, 2597 (2007).
B. Quesnel, C. Preudhomme, P. Fenaux, Leuk. Lymphoma 22, 11 (1996).
B. Scheijen, J. Jonkers, D. Acton, A. Berns, J. Virol. 71, 9 (1997).
B. T. Spike, K. F. Macleod, Cell Cycle 4, 42 (2005).
Breuer et al., 2005, Lung Cancer. 48:299-306.
C. P. Hans et al., Blood 103, 275 (2004).
D. F. Dukers et al., Am. J. Pathol. 164, 873 (2004).
E. M. Hurt, B. T. Kawasaki, G. J. Klarmann, S. B. Thomas, W. L. Farrar, Br.J. Cancer 98, 756 (2008).
F. J. van Kemenade et al., Blood 97, 3896 (2001).
F. M. Raaphorst et al., Am. J. Pathol. 157, 709 (2000).
F. M. Raaphorst et al., Am. J. Pathol. 164, 533 (2004).
F. M. Raaphorst, C. J. Meijer, A. P. Otte, Cancer Res. 62, 618 (2002).
F. Zhang, L. Sui, T. Xin, Exp. Oncol. 30, 70 (2008).
G. D. van et al., Exp. Hematol. 35, 1538 (2007).
G. P. Dimri et al., Cancer Res. 62, 4736 (2002).
G. V. Glinsky, O. Berezovska, A. B. Glinskii, J. Clin. Invest 115, 1503-1521 (2005).
H. Cui et al., Am. J. Pathol. 170, 1370-1378 (2007).
H. Koga et al., Oncogene 18, 3799 (1999).
H. Vekony et al., J. Clin. Pathol. 61, 744 (2008).
H. Wang et al., J. Cancer Res. Clin. Oncol. 134, 535 (2008).
I. B. Engelsen et al., Br. J. Cancer 98, 1662 (2008).
J. B. Arnes, K. Collett, L. A. Akslen, Histopathology 52, 370 (2008).
J. C. van Galen et al., J. Clin. Pathol. 60, 167 (2007).
J. H. Kim et al., Breast 13, 383-388 (2004).
J. H. Kim et al., Cancer Lett. 203, 217 (2004).
J. H. Liu et al., J. Surg. Oncol. 97, 267 (2008).
J. J. Jacobs et al., Genes Dev. 13, 2678 (1999).
J. J. Jacobs, K. Kieboom, S. Marino, R. A. DePinho, L. M. van, Nature 397, 164 (1999).
J. M. Adams, S. Cory, Cancer Surv. 15, 119 (1992).
J. Wei, L. Zhai, J. Xu, H. Wang, J. Biol. Chem. 281, 22537 (2006).
J. Yang et al., Proc. Natl. Acad. Sci. U. S. A 104, 10494 (2007).
K. H. Huang, J. H. Liu, X. X. Li, L. B. Song, M. S. Zeng, Nan. Fang Yi. Ke. Da. Xue. Xue. Bao. 27, 973 (2007).
K. Mihara et al., Blood 107, 305 (2006).
K. Mihara et al., Rinsho Ketsueki 48, 659 (2007).
K. Nowak et al., Nucleic Acids Res. 34, 1745 (2006).
L. B. Song et al., Cancer Res. 66, 6225 (2006).
L. Liu, L. G. Andrews, T. O. Tollefsbol, Oncogene 25, 4370-4375 (2006).
L. M. van et al., Cell 65, 737 (1991).
L. M. van, M. Frasch, E. Wientjens, A. Berns, Nature 353, 353 (1991).
Lessard et al., 2003, Nature 423:255-260.
M. Chowdhury et al., Leukemia 21, 1116 (2007).
M. Courel, L. Friesenhahn, J. A. Lees, Dev. Dyn. 237, 1232 (2008).
M. J. Alkema, J. Wiegant, A. K. Raap, A. Berns, L. M. van, Hum. Mol. Genet. 2, 1597 (1993).
M. K. Kang et al., Br. J. Cancer 96, 126 (2007).
M. S. Lindstrom, U. Klangby, K. G. Wiman, Oncogene 20, 2171 (2001).
M. Sanchez-Beato et al., J. Pathol. 204, 528 (2004).
M. Sawa et al., Int. J. Hematol. 82, 42-47 (2005).
N. Kozakowski, A. Soleiman, J. Pammer, Pathol. Oncol. Res. 14, 9 (2008).
P. R. Solomon et al., Indian J. Med. Res. 127, 52 (2008).
Park et al., 2003, Nature. 423:302-305.
R. H. Breuer et al., Neoplasia. 6, 736 (2004).
R. Kuppers, U. Klein, M. L. Hansmann, K. Rajewsky, N. Engl. J. Med. 341, 1520 (1999).
Reinisch et al., 2006, Histol Histopathol. 21:1143-1149.
S. Bea et al., Blood 93, 4365 (1999).
S. Bea et al., Cancer Res. 61, 2409 (2001).
S. Faderl et al., Clin. Cancer Res. 5, 1855 (1999).
S. Faderl et al., Cytokines Cell Mol. Ther. 5, 159 (1999).
S. J. Kuerbitz, J. Malandro, N. Compitello, S. B. Baylin, J. R. Graff, Cell Growth Differ. 10, 27 (1999).
S. K. Li et al., J. Biol. Chem. (2008).
S. Liu et al., Cancer Res. 66, 6063 (2006).
S. Vonlanthen et al., Br. J. Cancer 84, 1372 (2001).
S. W. Bruggeman et al., Cancer Cell 12, 328 (2007).
V. Fernandez, E. Hartmann, G. Ott, E. Campo, A. Rosenwald, J. Clin. Oncol. 23, 6364 (2005).
V. Hayry et al., Acta Neuropathol. (2008).
V. Hayry et al., Neuropathol. Appl. Neurobiol. (2008).
W. A. Dik et al., Leukemia 19, 1948 (2005).
W. J. Guo, S. Datta, V. Band, G. P. Dimri, Mol. Biol. Cell 18, 536 (2007).
W. P. de Boer, J. J. Oudejans, C. J. Meijer, J. Lankelma, Bioinformatics. 19, 2000 (2003).
Wiederschain et al., 2007, Mol Cell Biol. 27(13):4968-4967.
Y. Haupt, G. Barri, J. M. Adams, Mol. Biol. Rep. 17, 17 (1992).
Y. Haupt, M. L. Bath, A. W. Harris, J. M. Adams, Oncogene 8, 3161-3164 (1993).

Also Published As

Publication number Publication date
AU2013348009A1 (en) 2015-06-04
JP2019031509A (ja) 2019-02-28
DK2922828T3 (da) 2020-08-31
US20150315182A1 (en) 2015-11-05
JP6918898B2 (ja) 2021-08-11
MA38208B1 (fr) 2021-12-31
US20200024260A1 (en) 2020-01-23
NZ708909A (en) 2019-11-29
KR102455889B1 (ko) 2022-10-17
WO2014081906A2 (en) 2014-05-30
US11180483B2 (en) 2021-11-23
MX2021009892A (es) 2021-09-14
EP2922828B1 (en) 2020-07-08
SA517381847B1 (ar) 2021-07-17
CN111423417B (zh) 2022-11-15
PE20151413A1 (es) 2015-10-23
EP2922828A2 (en) 2015-09-30
ES2821529T3 (es) 2021-04-26
KR20150086345A (ko) 2015-07-27
WO2014081906A3 (en) 2014-07-17
NZ746607A (en) 2019-11-29
CA2892045A1 (en) 2014-05-30
MX385385B (es) 2025-03-18
US10428050B2 (en) 2019-10-01
IL238871B (en) 2019-03-31
BR112015011760B1 (pt) 2022-12-06
AU2013348009B2 (en) 2018-05-17
TW201427972A (zh) 2014-07-16
KR20220016305A (ko) 2022-02-08
PH12015501130A1 (en) 2015-08-03
CN111423417A (zh) 2020-07-17
SG11201503982XA (en) 2015-06-29
AR093579A1 (es) 2015-06-10
ECSP15019948A (es) 2016-01-29
JP2016504290A (ja) 2016-02-12
JP6617186B2 (ja) 2019-12-11
KR102356487B1 (ko) 2022-02-08
CL2015001377A1 (es) 2016-02-19
IL238871A0 (en) 2015-07-30
ZA201503642B (en) 2020-10-28
BR112015011760A2 (pt) 2017-07-11
IL265253A (en) 2019-05-30
JP6412503B2 (ja) 2018-10-24
KR20210088740A (ko) 2021-07-14
EA035349B1 (ru) 2020-05-29
TWI623531B (zh) 2018-05-11
EA201890142A1 (ru) 2018-06-29
NI201500072A (es) 2016-01-18
PH12015501130B1 (en) 2023-01-27
EA031405B1 (ru) 2018-12-28
PL2922828T3 (pl) 2020-12-28
CN104918919A (zh) 2015-09-16
US20220064150A1 (en) 2022-03-03
EP2922828A4 (en) 2016-07-27
MX2015006469A (es) 2015-10-29
KR102275676B1 (ko) 2021-07-12
UA118094C2 (uk) 2018-11-26
CR20150294A (es) 2015-08-20
CU20150053A7 (es) 2015-11-27
HK1215032A1 (zh) 2016-08-12
JP2020055815A (ja) 2020-04-09
PT2922828T (pt) 2020-10-12
CA2892045C (en) 2022-05-31
AU2013348009C1 (en) 2019-08-08
EA201590992A1 (ru) 2015-11-30
CU24387B1 (es) 2019-03-04
SG10201600149VA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
US11180483B2 (en) Substituted reverse pyrimidine Bmi-1 inhibitors
US10370371B2 (en) Substituted pyrimidine Bmi-1 inhibitors
US10584115B2 (en) Substituted pyridine and pyrazine BMI-1 inhibitors
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000